Literature DB >> 18616554

Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.

Woodie M Zachry1, Quynhchau D Doan, Jerry D Clewell, Brien J Smith.   

Abstract

PURPOSE: Although antiepileptic drugs (AEDs) with multisource generic alternatives are becoming more prevalent, no case-control studies have been published examining multisource medication use and epilepsy-related outcomes. This study evaluated the association between inpatient/emergency epilepsy care and the occurrence of a recent switch in AED formulation.
METHODS: A case-control analysis was conducted utilizing the Ingenix LabRx Database. Eligible patients were 12-64 years of age, received >or=145 days of AEDs in the preindex period, had continuous eligibility for 6 months preindex, and no prior inpatient/emergency care. Cases received care between 7/1/2006 and 12/31/2006 in an ambulance, emergency room, or inpatient hospital with a primary epilepsy diagnosis. Controls had a primary epilepsy diagnosis in a physician's office during the same period. The index date was the earliest occurrence of care in each respective setting. Cases and controls were matched 1:3 by epilepsy diagnosis and age. Odds of a switch between "A-rated" AEDs within 6 months prior to index were calculated.
RESULTS: Cases (n = 416) had 81% greater odds of having had an A-rated AED formulation switch [odds ratio (OR) = 1.81; 95% confidence interval (CI) = 1.25 to 2.63] relative to controls (n = 1248). There were no significant differences between groups regarding demographics or diagnosis. Significant differences were found with regard to medical coverage type (case Medicaid = 4.6%, control Medicaid = 1.8%, p = 0.002). Post hoc analysis results excluding Medicaid recipients remained significant and concordant with the original analysis. DISCUSSION: This analysis found an association between patients receiving epilepsy care in an emergency or inpatient setting and the recent occurrence of AED formulation switching involving A-rated generics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18616554     DOI: 10.1111/j.1528-1167.2008.01703.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

1.  Switching of antiepileptic drug formulations.

Authors:  J Nile Barnes; Karen L Rascati
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

2.  [Change from original preparations to generics. A case example with oxcarbazepine].

Authors:  G Hagemann; J Zinke; M Fuchs; O W Witte
Journal:  Nervenarzt       Date:  2010-12       Impact factor: 1.214

Review 3.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

4.  A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.

Authors:  Yang Yu; Steven Teerenstra; Cees Neef; David Burger; Marc Maliepaard
Journal:  Br J Clin Pharmacol       Date:  2016-01-15       Impact factor: 4.335

5.  Generic substitution of antiepileptic drugs: What's a clinician to do?

Authors:  Michael Privitera
Journal:  Neurol Clin Pract       Date:  2013-04

6.  Epilepsy: Generic substitution: are antiepileptic drugs different?

Authors:  Carl W Bazil
Journal:  Nat Rev Neurol       Date:  2009-11       Impact factor: 42.937

7.  Interchangeability of generic anti-epileptic drugs: a quantitative analysis of topiramate and gabapentin.

Authors:  Marc Maliepaard; Nikola Banishki; Christine C Gispen-de Wied; Steven Teerenstra; André J Elferink
Journal:  Eur J Clin Pharmacol       Date:  2011-04-15       Impact factor: 2.953

Review 8.  Bioequivalence of antiepileptic drugs: how close is close enough?

Authors:  Barry E Gidal
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

9.  Substitution of anticonvulsant drugs.

Authors:  Bernhard J Steinhoff; Uwe Runge; Otto W Witte; Hermann Stefan; Andreas Hufnagel; Thomas Mayer; Günter Krämer
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

Review 10.  Requirements for generic anti-epileptic medicines: a regulatory perspective.

Authors:  Marc Maliepaard; Yechiel A Hekster; Arnoud Kappelle; Eugène P van Puijenbroek; André J Elferink; Jan Welink; Christine C Gispen-de Wied; Frits J F Lekkerkerker
Journal:  J Neurol       Date:  2009-07-15       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.